TY - JOUR
T1 - Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Cystoid Macular Edema
AU - Mansour, Ahmad M.
AU - Sheheitli, Huda
AU - Kucukerdonmez, Cem
AU - Sisk, Robert A.
AU - Moura, Raphael
AU - Moschos, Marilita M.
AU - Lima, Luiz H.
AU - Al-Shaar, Laila
AU - Arevalo, J. Fernando
AU - Maia, Mauricio
AU - Foster, Robert E.
AU - Kayikcioglu, Ozcan
AU - Kozak, Igor
AU - Kurup, Shree
AU - Zegarra, Hernando
AU - Gallego-Pinazo, Roberto
AU - Hamam, Rola N.
AU - Bejjani, Riad A.
AU - Cinar, Esat
AU - Erakgün, Ethem T.
AU - Kimura, Alan
AU - Teixeira, Anderson
N1 - Publisher Copyright:
© Ophthalmic Communications Society, Inc.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Purpose: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema. Methods: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test. Results: There were a total of 45 eyes from 34 patients with a mean age of 32.7 years (range 16-57) and mean follow-up of 15.5 ± 13.0 months. At Month 3 after the first injection, mean initial best-corrected visual acuity improved from 0.61 ± 0.38 (20/81) to 0.37 ± 0.16 (20/47) (P = 0.012), whereas mean central macular thickness (m) decreased from 506 ± 288 m to 311.7 ± 71.6 m (P < 0.001) and mean intraocular pressure increased from 15.7 ± 2.3 mmHg to 19.8 ± 11.0 mmHg (P = 0.01). Fourteen eyes had multiple injections (1-7 reinjections) at a mean interval of 6 months. Treatment effect was durable with multiple injections, but with seven eyes developing visually significant cataracts. Conclusion: Best-corrected visual acuity improved up to 4 months in around half of the eyes. Eyes that benefited the most were pseudophakic, steroid nonresponsive, with large initial central macular thickness, and profuse fluorescein dye leakage.
AB - Purpose: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema. Methods: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test. Results: There were a total of 45 eyes from 34 patients with a mean age of 32.7 years (range 16-57) and mean follow-up of 15.5 ± 13.0 months. At Month 3 after the first injection, mean initial best-corrected visual acuity improved from 0.61 ± 0.38 (20/81) to 0.37 ± 0.16 (20/47) (P = 0.012), whereas mean central macular thickness (m) decreased from 506 ± 288 m to 311.7 ± 71.6 m (P < 0.001) and mean intraocular pressure increased from 15.7 ± 2.3 mmHg to 19.8 ± 11.0 mmHg (P = 0.01). Fourteen eyes had multiple injections (1-7 reinjections) at a mean interval of 6 months. Treatment effect was durable with multiple injections, but with seven eyes developing visually significant cataracts. Conclusion: Best-corrected visual acuity improved up to 4 months in around half of the eyes. Eyes that benefited the most were pseudophakic, steroid nonresponsive, with large initial central macular thickness, and profuse fluorescein dye leakage.
KW - cystoid macular edema
KW - dexamethasone implant
KW - intraocular pressure
KW - retinitis pigmentosa
UR - http://www.scopus.com/inward/record.url?scp=85013469748&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013469748&partnerID=8YFLogxK
U2 - 10.1097/IAE.0000000000001542
DO - 10.1097/IAE.0000000000001542
M3 - Article
C2 - 28221257
AN - SCOPUS:85013469748
SN - 0275-004X
VL - 38
SP - 416
EP - 423
JO - Retina
JF - Retina
IS - 2
ER -